Microfluidic Platforms aim to Accelerate CAR-T cell therapy manufacturing

Researchers at MIT’s Charles Stark Draper Laboratory Draper Laboratory – a not-for-profit research and development company focused on development of technical solutions for health, energy, national security and space – have recently announced the development of microfluidic platforms to accelerate the manufacturing of CAR-T therapies. The current focus is on two platforms: one for enrichment

Moving Cell and Gene Therapies Forward – Updates from the EMA

On 16 December 2016, the European Medicines Agency (EMA), together with the European Biopharmaceutical Enterprises (EBE) held the fifth annual “Optimizing the development of ATMPs to meet patient needs” regulatory conference on the optimization of the development of advanced therapy medicinal products (ATMPs) to meet patient needs in London, UK. The conference featured a group of international pharmaceutical

In vivo delivery of genes and drugs via nanoparticles can now be screened quickly via DNA “barcodes,” new study shows

The science of developing nanoparticles as delivery tools for various biologically active agents – genes and drugs – has come a long way. Material science advances have allowed for the construction of nanoparticles with different physicochemical properties, which has, in turn, resulted in remarkable advances, particularly in the area of nucleic acid delivery for the

The new akronbiotech.com ushers Akron into the future

Following an eventful week at Phacilitate’s Cell and Gene Therapy World Forum in Miami, Akron just unveiled its new website, which can be accessed at www.akronbiotech.com. The new website sports a brand new look alongside a refreshed logo, which features Akron’s recognizable image that has been updated for the new year. Since 2006, Akron gone through multiple changes, and the

Creating cellular function: Microparticles that act as heart stem cells developed

If the development of genetic editing approaches to induce functional changes to cell behavior to enhance their efficacy has led to remarkable advances in gene-engineered cell therapy, the development, on the other hand, of synthetic systems for tissue engineered and regenerative medicine-based therapies has made inroads as a robust, fully-controllable bottom-up approach to cell and gene